Form 4: Tarsus CHRO Sells Shares Under 10b5-1 Plan

Tarsus Pharmaceuticals' Chief Human Resources Officer, Dianne C. Whitfield, sold 7,397 shares of common stock for $80.1 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc. (TARS), reported a sale of common stock.
• The transaction involved the disposition of 7,397 shares of Tarsus Pharmaceuticals common stock.
• The shares were sold at a price of $80.1 per share.
• The total value of the shares sold was approximately $592,559.70 (7,397 shares * $80.1/share).
• Following this transaction, Ms. Whitfield beneficially owns 38,958 shares of common stock directly.
• The sale was executed on December 16, 2025, pursuant to a Rule 10b5-1 trading plan adopted by Ms. Whitfield on September 12, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale of shares by an insider, while a disposition, was conducted under a pre-arranged Rule 10b5-1 trading plan. This indicates a planned liquidity event rather than a reaction to new material non-public information, thus mitigating any potential negative sentiment typically associated with insider selling.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice for corporate executives to manage personal liquidity and diversification. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a Chief Human Resources Officer under a 10b5-1 plan is generally viewed as a routine personal financial management event and is unlikely to have a significant impact on shareholder perception or company valuation.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale of common stock by an executive under a Rule 10b5-1 trading plan. Such transactions are typically for personal financial planning purposes and do not reflect new information about the company's operational performance or future prospects. Therefore, this filing alone does not provide a basis to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Tarsus Pharmaceuticals, TARS, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, Dianne C. Whitfield, Chief Human Resources Officer